Diabetes Wellness Forum: Revisiting Landmark Trials in 2026
Overview of the Episode
In the latest episode of the Diabetes Wellness Forum, titled “Empagliflozin & Sitagliptin – Landmark Trials Revisited in 2026,” Dr. Nandita Mohan from Medic Helpline engages in a discussion with Dr. Dheeraj Kapoor, Chief of Endocrinology at Artemis Hospital in Gurgaon, and Dr. Swayamsidha Mangaraj, Professor in the Department of Endocrinology at IMS and SUM Hospital in Bhubaneswar. The conversation focuses on essential aspects of diabetes care as it stands in 2026.
Role of Empagliflozin and Sitagliptin
Empagliflozin and Sitagliptin are well-established agents widely utilized for the long-term management of type 2 diabetes. As diabetes care evolves through both major innovations and micro-innovations, new fixed-dose combinations such as Empagliflozin–Sitagliptin FDC and Empagliflozin–Sitagliptin–Metformin FDC have been developed. These combinations provide greater convenience and therapeutic synergy for patients.
Importance of Revisiting Evidence
Revisiting the evidence supporting the use of Empagliflozin and Sitagliptin is crucial for optimizing their application in routine clinical practice. A thorough understanding of their complementary mechanisms and relevant clinical data will enable healthcare providers to implement these treatments more effectively in 2026, ultimately improving patient outcomes.
Key Clinical Questions Addressed
During the episode, the experts tackle three significant clinical questions:
1. What are the key benefits of Empagliflozin based on landmark clinical trial evidence over the last decade?
2. What are the key benefits of Sitagliptin based on landmark clinical trial evidence over the last one and a half decades?
3. In which patient profiles should the Empagliflozin–Sitagliptin–Metformin FDC be considered?